Even though we live in the most technologically advanced times, there are still diseases with ineffective treatments or none at all. This is where up and coming healthcare companies are looking to make it big. The market potential is massive for these companies and it makes them some of the most lucrative penny stocks.
A penny stock is any equity that trades below $5. When trading penny stocks you must be prepared to handle insane amounts of volatility. That’s just due to the speculative nature of cheap stocks like these.
This volatility can result in massive profits if traded properly. If you are looking for some penny stocks to buy, here is a list of penny stocks you may want to research as the healthcare sector begins to surge in November:
Healthcare Penny Stocks To Watch: AVEO Pharmaceuticals Inc. (AVEO)
Kicking things off is AVEO Pharmaceuticals Inc. (AVEO Stock Report). The primary focus of AVEO is advancing targeted medicines for oncology and other unmet needs.
The company has already marketed Tivozanib (TIVO-1) which is a huge leg up on other companies’ in this sector. In terms of overall pipeline size, the company has 10 other potential treatments.
AVEO recently reported its Q3 financial results as well as a business update. The business update helped wrap up all of AVEO’s developments over this last quarter as well as revealing future goals. The company is planning on making a NDA submission for Tivozabib (TIVO-3) after its promising Phase 3 trial. This penny stock news has prompted AVEO’s stock price to fly 18.5% during premarket hours on November 12th.
Healthcare Penny Stocks To Watch: Clovis Oncology Inc. (CLVS)
Clovis Oncology Inc. (CLVS Stock Report) has been one of the penny stocks to watch this quarter. Though this isn’t a penny stock by definition anymore, investors looking for cheap stocks continue to watch. Among a series of positive releases, Clovis reported favorable quarterly results early on in the month.
Aside from that, Clovis also raised its 2019 outlook for net product revenue. The new range falls between $141 million and $147 million. The company beat on both EPS and sales estimates. Furthermore, it was revealed today that Clovis’ anti-cancer agent, Rubraca was approved for reimbursement by the Italian Medicines Agency.
- 4 Penny Stocks To Buy For Under $1 Right Now
- Top 10 Penny Stocks On Robinhood To Watch For November 2019
- Best Penny Stocks To Trade Right Now? 1 Up 48% This Quarter
- 4 Penny Stocks To Watch In November After Latest Milestones
Why is this so important? Rubraca is now available as a monotherapy treatment for people with relapsed ovarian, fallopian tube or peritoneal cancer. Also generically known as Rucaparib, it has received approval in several EU countries. This obviously opens a global opportunity for the company in addition to its previously announced sales and EPS growth. Can CLVS stock head higher before the end of November?
Healthcare Penny Stocks To Watch: Agile Therapeutics Inc. (AGRX)
We have talked about Agile Therapeutics Inc. (AGRX Stock Report) quite a bit. In case you have missed some of our past articles, Agile Therapeutics is a women’s healthcare company. It focuses on meeting the unmet needs of today’s women.
In order to do this, one of its products it’s a weekly contraceptive patch known as Twirla. This provides an alternative to the daily contraceptive pill that is widely used.
[Read More On Agile Therapeutics] The Best Penny Stocks To Buy Or Sell Right Now?
Agile’s price action over the 13 days has been quite impressive. Since October 31st’s trading session, the penny stock has risen from $0.374 all the way to $2.15. This sharp rise has resulted in some price consolidation.
As we said earlier this week, “The FDA assigned a PDUFA goal date of November 16. Thought this is later in the week, this could be reason enough to make it a penny stock to watch. This event is for the completion of the FDA’s review of Twirla’s New Drug Application.”
Healthcare Penny Stocks To Watch: Moleculin Biotech Inc. (MBRX)
The final company on this list is Moleculin Biotech Inc. (MBRX Stock Report). Moleculin is focused on developing treatment for highly resistant cancers. As of now, the company has 9 potential treatment plans in its clinical pipeline. Its lead product candidate is WP1220 and is expected to enter its phase 2 trials in 2020.
Moleculin also had some recent penny stock news that is bolstering its stock price upwards this week. So, what was the news exactly? The company announced that the FDA approved its request for Investigational New Drug status for its STAT3 Inhibitor.
This will allow its treatment, WP1066, to be used in a Phase 1 trial for children with recurrent malignant brain tumors. This has resulted in an early 7% gain for the company’s stock. In addition, Moleculin reported on Wednesday that it began preclinical testing of its WP1122 to treat “highly glycolytic tumors.” This includes things like pancreatic cancer and “glioblastoma,” a fast forming type of brain cancer.
“WP1122 represents an opportunity to attack the metabolism of cancer by exploiting the Warburg principle, which explains that some tumors are highly dependent on glycolysis, a specific metabolism of glucose, for growth and survival,” commented Walter Klemp, Moleculin’s Chairman, and CEO of Moleculin.